ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives. ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology Investor Relations Contact:
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology (NASDAQ:ALXO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALXO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZenMarketBeat
- ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual MeetingGlobeNewswire
- ALX Oncology (NASDAQ:ALXO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALXO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
- ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- ALX Oncology to Present at Upcoming Investor ConferencesGlobeNewswire
ALXO
Earnings
- 11/7/25 - Miss
ALXO
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/7/25 - Form 10-Q
- ALXO's page on the SEC website